Development of an Activity Index for Localized Scleroderma (Morphea) PDF Print E-mail
Wednesday, 21 September 2011 00:39
E. Lanciano, A. CHIALà, E. Praino, V. Grattagliano, M. Covelli, F. Iannone, G. Lapadula Reumatologia Universitaria, Policlinico, Bari, Italy
Ann Rheum Dis 2011;70(Suppl3):481

Background: Morphea is a skin disorder characterized by fibrosis. It affects more commonly females than males (ratio 3:1) with an year incidence of 27/million. Recently, some studies have shown that methotrexate and UVA-1 phototherapy may be effective in the treatment of Morphea. However, an index to monitor the disease activity and to evaluate the response to the therapy is not available. Aim of this study was to construct an index for Morphea by considering some parameters of objective evaluation of the skin lesions.

Methods: We enrolled 8 patients with morphea and for each of them the degree of infiltration of the lesions, the color of the margins and the size in cm2 were evaluated. In case of multiple lesions only the largest was considered. To each of these parameters a score from 0 (remission) to 3 (the highest activity) was assigned. The color of the margins indistinguishable from normal surrounding skin was considered as 0, as 1when the colour was dull beige, as 2 when it was pinkish, and as 3 when the colour was clearly red. With regard to the degree of infiltration the modified Rodnan Skin Score was used (0 for normal skin, 1 in case of mild infiltration, 2 in case of moderate infiltration and 3 for severe infiltration). As far as the size of lesions concerns, score 1 was assigned to lesions up to 50 cm2, score 2 to those between 50 and 100 cm2, score 3 to those larger than 100 cm2. The index of disease activity was indicated as high if between 6 and 9, moderate if between 4 and 6, low if between 1 and 3. While a complete resolution of lesions was considered as 0.The patients received methotrexate at a dose of 10-15 mg per week and methylprednisolone at a dose of 4 mg daily for 6 months. Clinical evaluation was performed at 3, 6, and 12months

Results: In all cases we had a good clinical response after 3 months of treatment,with almost complete resolution after 6 months. At baseline we evaluated an average index of 8, after 3 months it was equal to 4.25, at 6 months the index was estimated at 3, and after further 6 months free of therapy the index was unchanged.

Conclusions: This pilot study provided evidence that a combined therapy of methotrexate and low dose steroids may be effective to treat morphea. Further studies on larger cohort of patients are needed to validate this activity index.

For a link to the original abstract, please click here.
More articles :

» Positive Phase II Results for AIMSPRO In Scleroderma Announced

announced yesterday, positive results from its Double-Blind Placebo-Controlled Phase II Clinical Study evaluating the safety and tolerability of AIMSPRO given as a monotherapy to patients with Late Stage Established Diffuse Cutaneous Systemic...

» Platelet Gel In The Treatment Of Severe Scleroderma Skin Ulcers

Dilia Giuggioli, Michele Colaci, Andreina Manfredi, Mariateresa Mariano and Clodoveo FerriSystemic sclerosis (SSc) is characterized by microvascular damage and fibrosis of the skin and internal organs. Non-healing skin ulcers, mainly non-venous leg...

» GERD and Scleroderma

is an autoimmune disease that causes the skin, and sometimes other organs of the body, to become hard and thick. In the diffuse form of scleroderma, the esophagus and gastrointestinal tract are often affected. GERD, or gastroesophageal reflux...

» Rheumatologist Receives Scleroderma Foundation's Lifetime Achievement Award

In a recent article, it was reported that ,  Gerald P. Rodnan Professor of Medicine, , received the 's Lifetime Achievement Award in recognition of his service to the community. The award is the foundation's highest honor and is presented to...

» Amira Pharmaceuticals Announces Efficacy of LPA1 Antagonist in a Preclinical Model of Scleroderma

Amira Pharmaceuticals, Inc. announced today that their collaborators, Andrew Tager, M.D. and Flavia V. Castelino, M.D. of Massachusetts General Hospital, Harvard Medical School, will present a preclinical proof-of-concept study which demonstrates...

» Researchers Gain Deeper Insights Into Causes And New Treatment Strategies For Scleroderma

Using mice, lab-grown cells and clues from a related disorder, Johns Hopkins researchers have greatly increased understanding of the causes of , showing that a critical culprit is a defect in the way certain cells communicate with their structural...

Add comment

Do feel free to leave your comments, as they would add value and knowledge to the community. However, please refrain from making any disparaging, uninformed, or unrelated comments. Thanks :)

Security code


Wise Words

"Happiness can only be found if you free yourself from all other distractions"
Saul Bellow

"Never let your sense of morals prevent you from doing what's right"
Isaac Asimov

"Before someone's tomorrow has been taken away, cherish those you love, appreciate them today"
Michelle C. Ustaszeski